NCT05575830View on ClinicalTrials.gov

Immune Response of Shingrix Vaccine in People Living With HIV (> 50 y.o.) Compared to Age-matched Controls

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

225

Participants

Timeline

Start Date

December 14, 2022

Primary Completion Date

April 16, 2025

Study Completion Date

March 31, 2026

Conditions
RZV Vaccine (Shingrix ®)
Interventions
BIOLOGICAL

Recombinant Zoster Vaccine

Shingrix® vaccine will be administered in two vaccinations on Day0 and Day60

Trial Locations (10)

1011

Centre Hospitalier Universitaire Vaudoise (CHUV), Lausanne

1205

University Hospitals of Geneva, Geneva

3010

Bern University Hospital (Inselspital), Bern

4031

University Hospital Basel, Basel

6900

Ente Ospedaliero Cantonale, Lugano

8091

University Hospital Zurich, Zurich

9007

Kantonsspital, Sankt Gallen

33000

SMIT - Service de Maladies Infectieuses et Tropicales Le Tripode -Groupe Hospitalier Pellegrin, Bordeaux

33075

Hôpital Saint-André, CHU de Bordeaux, Bordeaux

33604

CHU de Bordeaux - Hôpital Haut-Lévèque, Pessac

All Listed Sponsors
lead

Calmy Alexandra

OTHER